Overall survival (OS) by treatment group for (A) all patients, (B) patients with indolent non-Hodgkin lymphoma, and (C) patients with mantle-cell lymphoma. Note: Censored values are represented by a vertical bar. BR, bendamustine plus rituximab; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CVP, rituximab plus cyclophosphamide, vincristine, and prednisone.